Electrocardiographic findings and global coronary risk assessment.

ment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998; 97: 1702–7. [13] Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 668–98. [14] Fareed J, Jeskie W, Hoppensteadt D, Clarizo R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Sem Thromb Hemost 1996; 22: 77–91. [15] Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000; 35: 169–712. [16] Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecularweight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355: 1936–42. [17] Klein W, Buchwald A, Hillis SE et al for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61–8. [18] The FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553–62. [19] Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561–8. [20] FRagmin and Fast Revascularization during InStability in Coronary artery disease Investigators. Long-term lowmolecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet 1999; 354: 701–7. 268 Editorials